Biogen Says Another Falls Ill After Taking MS Drug

Law360, New York (October 29, 2008, 12:00 AM EDT) -- For the third time since reintroducing the treatment to the market, Biogen Idec Inc. has said that a multiple sclerosis patient treated with its drug Tysabri has developed a rare but potentially fatal brain disease.

In a filing with the U.S. Securities and Exchange Commission on Wednesday, Biogen said it had notified agencies of a confirmed case of progressive multifocal leukoencephalopathy in a person using the drug to treat multiple sclerosis. The company said the patient received 14 infusions of Tysabri monotherapy and is under the...
To view the full article, register now.